Unicycive Therapeutics (NASDAQ:UNCY) Price Target Raised to $7.50 at HC Wainwright

Unicycive Therapeutics (NASDAQ:UNCY) had its price target boosted by HC Wainwright from $4.00 to $7.50 in a report released on Tuesday,Benzinga reports. The firm currently has a “buy” rating on the stock.

Unicycive Therapeutics Trading Up 0.5 %

Shares of NASDAQ UNCY opened at $0.55 on Tuesday. The firm has a market cap of $56.93 million, a P/E ratio of -0.57 and a beta of 2.26. The business’s 50 day moving average is $0.58 and its 200-day moving average is $0.57. Unicycive Therapeutics has a 1-year low of $0.20 and a 1-year high of $1.60.

Unicycive Therapeutics (NASDAQ:UNCY) last posted its quarterly earnings data on Thursday, March 27th. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.13). Analysts forecast that Unicycive Therapeutics will post -0.23 EPS for the current year.

Institutional Investors Weigh In On Unicycive Therapeutics

Several institutional investors have recently made changes to their positions in UNCY. Northern Trust Corp raised its position in shares of Unicycive Therapeutics by 142.4% in the 4th quarter. Northern Trust Corp now owns 58,181 shares of the company’s stock valued at $46,000 after buying an additional 34,183 shares in the last quarter. XTX Topco Ltd bought a new position in Unicycive Therapeutics in the third quarter valued at approximately $29,000. Virtu Financial LLC raised its position in Unicycive Therapeutics by 566.8% during the third quarter. Virtu Financial LLC now owns 73,975 shares of the company’s stock valued at $30,000 after purchasing an additional 62,881 shares in the last quarter. Geode Capital Management LLC raised its position in Unicycive Therapeutics by 30.3% during the fourth quarter. Geode Capital Management LLC now owns 524,487 shares of the company’s stock valued at $417,000 after purchasing an additional 122,089 shares in the last quarter. Finally, Acuta Capital Partners LLC lifted its stake in Unicycive Therapeutics by 16.4% during the fourth quarter. Acuta Capital Partners LLC now owns 2,303,000 shares of the company’s stock worth $1,829,000 after purchasing an additional 323,801 shares during the last quarter. 40.42% of the stock is currently owned by institutional investors.

Unicycive Therapeutics Company Profile

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.